Lv2
120 积分 2023-04-14 加入
Is there a role for the no observed adverse effect level in safety pharmacology?
1个月前
已完结
Sigma-1 (σ1) Receptor in Memory and Neurodegenerative Diseases
1个月前
已完结
Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics
1个月前
已完结
Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeutics
1个月前
已完结
PRSS3 promotes tumour growth and metastasis of human pancreatic cancer
1个月前
已完结
Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview
1个月前
已完结
Potential pharmacological interventions in polycystic kidney disease
1个月前
已完结
Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview
2个月前
已完结
MicroRNA-17: a new drug target for ADPKD
2个月前
已完结
Pharmacokinetics and Absorption, Distribution, Metabolism and Excretion of RGLS4326 in Mouse and Monkey, an Anti–miR-17 Oligonucleotide for the Treatment of Polycystic Kidney Disease
2个月前
已完结
皖公网安备34019202002308
